- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03463473
A Phase I Study of MSB2311 in Advanced Solid Tumors
December 11, 2023 updated by: Suzhou Transcenta Therapeutics Co., Ltd.
First-in-human, Open-label, Phase 1 Dose-Escalation Study of MSB2311, A Humanized Anti-PD-L1 Monoclonal Antibody in Subjects With Advanced Solid Tumors
This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors.
Study Overview
Status
Completed
Conditions
Detailed Description
This is a first-in-human (FIH), open-label, Phase 1 dose-Escalation Study of MSB2311, a humanized anti-PD-L1 monoclonal antibody, in subjects with advanced solid tumors.
Qualified subjects will be enrolled to receive their assigned dose regimen of MSB2311 until disease progression or intolerable toxicity, withdrawal of consent, or end of study, whichever occurs first.
The maximum treatment duration is 2 years.
During the study, subjects will be evaluated for safety and toxicity, PK/PD, immunogenicity, biomarkers, and anti-tumor activity of MSB2311.
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- South Texas Accelerated Research Therapeutics
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Able to understand and willing to sign the ICF.
- Male or female subject ≥ 18 years.
- Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors that are refractory to standard therapy, or for which no standard therapy exists.
- Subject has measurable disease per RECIST v1.1.
- ECOG Performance Status 0 to 1
- Subjects with life expectancy of ≥ 3 month
- No herbal/alternative medications prior to the first dose
- Must have adequate hematological, hepatic and renal function as defined in the protocol.
- Prior anti-tumor therapies of different kinds must have stopped before the first dose as defined by protocol
- Effective contraception for both male and female subjects if the risk of conception exists
Exclusion Criteria:
- Pregnant or nursing females.
- Any remaining AEs > grade 1 from prior anti-tumor treatment as per CTCAE v4. 03, with exception of the residual hair loss;
- Received a biologic G-CSF, GM-CSF or erythropoietin within 14 days prior to the first dose of study drug;
- Subjects who had prior treatment with an anti-PD-L1 product
- History of documented autoimmune disease except for autoimmune hypothyroidism and well-controlled Type 1 diabetes mellitus.
- W/o autoimmune condition requiring systemic treatment with immunosuppressive medications within 14 days before the planned first dose of study drug.
- Primacy central nervous system (CNS) malignancy or symptomatic CNS metastases are not allowed, with exceptions defined in protocol.
- Major surgery within the 28-days from the screening
- Subjects with idiopathic pulmonary fibrosis or unresolved active or chronic inflammatory pulmonary disease are excluded.
- History of human immunodeficiency virus (HIV) infection, active hepatitis B or C. HBV carriers
- History of primary immunodeficiency, stem cell or organ transplant, or previous clinical diagnosis of tuberculosis disease.
- Clinically significant acute infections 4 weeks and any infection 2 weeks prior to the first dose administration.
- Known allergies, hypersensitivity, or intolerance to protein-based therapies or with a history of any significant drug allergy
- Subjects who experienced immunotherapy-related adverse events (irAE) grade ≥ 3, or who had to discontinue prior anti-PD-1 treatment due to irAEs of any grade.
- Severe or uncontrolled cardiac disease requiring treatment as defined in protocol
- Any other serious underlying medical, psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, might impair the subject's benefit from the trial treatment
- Known history of hypersensitivity to any components of the MSB2311 product.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 3 mg/kg (Q3W) MSB2311 Injection
MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W) starting at 3 mg/kg.
|
An intravenous infusion with concentration from 3 mg/kg (Q3W)
Other Names:
|
Experimental: 10 mg/kg (Q3W) MSB2311 Injection
MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W) starting at 10 mg/kg.
|
An intravenous infusion with concentration from 10 mg/kg (Q3W)
Other Names:
|
Experimental: 20 mg/kg (Q3W) MSB2311 Injection
MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W) starting at 20 mg/kg.
|
An intravenous infusion with concentration from 20 mg/kg (Q3W)
Other Names:
|
Experimental: 10 mg/kg (Q2W) MSB2311 Injection
MSB2311 will be administered as an IV infusion once every 2weeks (Q2W) starting at 10 mg/kg.
|
An intravenous infusion with concentration from 10 mg/kg (Q2W)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of MSB2311
Time Frame: Up to 90 days following the last dose
|
Measured by number adverse events that are related to treatment
|
Up to 90 days following the last dose
|
Maximum tolerated dose or recommended phase 2 dose
Time Frame: Up to 90 days following the last dose
|
Measured by number of subjects experiencing DLT in each escalation cohort
|
Up to 90 days following the last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration versus time curve (AUC) for MSB2311
Time Frame: Up to 30 days following the last dose
|
Up to 30 days following the last dose
|
|
Peak Plasma concentration (Cmax)for MSB2311
Time Frame: Up to 30 days following the last dose
|
Incidence and quantity of anti-drug antibodies
|
Up to 30 days following the last dose
|
Volume of plasma from which MSB2311 is completely removed per unit time (CL)
Time Frame: Up to 30 days following the last dose
|
Up to 30 days following the last dose
|
|
The incidence of subjects generating anti-drug antibody
Time Frame: Up to 30 days following the last dose
|
Up to 30 days following the last dose
|
|
Objective response rate (ORR) as measured by RESISTv1.1
Time Frame: Up to 30 days following the last dose
|
Up to 30 days following the last dose
|
|
Duration of response (DOR) as measured by RESISTv1.1
Time Frame: Up to 30 days following the last dose
|
Up to 30 days following the last dose
|
|
Progression-free survival (PFS) as measured by RESISTv1.1
Time Frame: Up to 30 days following the last dose
|
Up to 30 days following the last dose
|
|
Best overall response as measured by RESISTv1.1
Time Frame: Up to 30 days following the last dose
|
Up to 30 days following the last dose
|
|
Overall survival (OS) as measured by RESISTv1.1
Time Frame: Up to 30 days following the last dose
|
Up to 30 days following the last dose
|
|
Elimination half-life and apparent plasma terminal phase elimination rate constant (t1/2 ) of MSB2311
Time Frame: Up to 30 days following the last dose
|
Up to 30 days following the last dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Yonggang Wu, MD, Suzhou Transcenta Therapeutics Co., Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 12, 2018
Primary Completion (Actual)
June 1, 2020
Study Completion (Actual)
June 1, 2020
Study Registration Dates
First Submitted
February 28, 2018
First Submitted That Met QC Criteria
March 6, 2018
First Posted (Actual)
March 13, 2018
Study Record Updates
Last Update Posted (Actual)
December 18, 2023
Last Update Submitted That Met QC Criteria
December 11, 2023
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MSB2311-CSP-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
Clinical Trials on 3 mg/kg Q3W MSB2311 Injection
-
Suzhou Transcenta Therapeutics Co., Ltd.Completed
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdCompletedGastric/Gastroesophageal Junction CancerChina
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingNasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell CarcinomaChina
-
GlaxoSmithKlineCompletedMuscular DystrophiesFrance, United States
-
MedImmune LLCCompletedHealthy SubjectsUnited States
-
Serum Institute of India Pvt. Ltd.PPDCompleted
-
Genor Biopharma Co., Ltd.RecruitingLymphoma | Advanced Solid Tumor | Recurrent Solid Tumor | Recurrent Lymphocyte Depleted Classical Hodgkin LymphomaChina
-
Sameem M. Abedin, MDRecruitingGraft-versus-host DiseaseUnited States
-
Healthgen Biotechnology Corp.RecruitingEmphysema Secondary to Congenital AATDUnited States
-
MedImmune LLCCompleted